Gilks CF - Search Results

1

World Health Organization/HIVResNet Drug Resistance Laboratory Strategy.

Bertagnolio S, Derdelinckx I, Parker M, Fitzgibbon J, Fleury H, Peeters M, Schuurman R, Pillay D, Morris L, Tanuri A, Gershy-Damet GM, Nkengasong J, Gilks CF, Sutherland D, Sandstrom P. Bertagnolio S, et al. Among authors: gilks cf. Antivir Ther. 2008;13 Suppl 2:49-57. Antivir Ther. 2008. PMID: 18575191

2

World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites.

Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. Jordan MR, et al. Among authors: gilks cf. Antivir Ther. 2008;13 Suppl 2:15-23. Antivir Ther. 2008. PMID: 18575188

3

Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment.

Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Bennett DE, et al. Among authors: gilks cf. Antivir Ther. 2008;13 Suppl 2:25-36. Antivir Ther. 2008. PMID: 18575189

4

The World Health Organization's global strategy for prevention and assessment of HIV drug resistance.

Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. Bennett DE, et al. Among authors: gilks cf. Antivir Ther. 2008;13 Suppl 2:1-13. Antivir Ther. 2008. PMID: 18578063

5

Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.

Phillips AN, Pillay D, Miners AH, Bennett DE, Gilks CF, Lundgren JD. Phillips AN, et al. Among authors: gilks cf. Lancet. 2008 Apr 26;371(9622):1443-51. doi: 10.1016/S0140-6736(08)60624-8. Lancet. 2008. PMID: 18440426

6

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerma T, De Cock K. Gilks CF, et al. Lancet. 2006 Aug 5;368(9534):505-10. doi: 10.1016/S0140-6736(06)69158-7. Lancet. 2006. PMID: 16890837

7

National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?

Beck EJ, Vitoria M, Mandalia S, Crowley S, Gilks CF, Souteyrand Y. Beck EJ, et al. Among authors: gilks cf. AIDS. 2006 Jul 13;20(11):1497-502. doi: 10.1097/01.aids.0000237365.18747.13. AIDS. 2006. PMID: 16847404

8

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.

Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, Lima VD, Günthard HF, Gilks C, Pillay D. Gupta RK, et al. Lancet Infect Dis. 2009 Jul;9(7):409-17. doi: 10.1016/S1473-3099(09)70136-7. Lancet Infect Dis. 2009. PMID: 19555900

9

Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).

Gilks CF, Walker AS, Dunn DT, Gibb DM, Kikaire B, Reid A, Musana H, Mambule I, Kasirye R, Robertson V, Ssali F, Spyer M, Pillay D, Yirrell D, Kaleebu P; DART Virology Group and Trial Team. Gilks CF, et al. Antivir Ther. 2012;17(7):1363-73. doi: 10.3851/IMP2253. Epub 2012 Jul 19. Antivir Ther. 2012. PMID: 22814125 Clinical Trial.

10

Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.

Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Granich RM, et al. Among authors: gilks cf. Lancet. 2009 Jan 3;373(9657):48-57. doi: 10.1016/S0140-6736(08)61697-9. Epub 2008 Nov 27. Lancet. 2009. PMID: 19038438

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

212 results

Search Page